U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06959888) titled 'A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations' on March 24.
Brief Summary: This is a phase 1 single dose, open-label, randomized, two-period, two-sequence, crossover study of ALG-055009 conducted in 1 cohort of healthy volunteers. The primary purpose of this study is to compare the single-dose pharmacokinetics of the 0.7 mg dose level of 2 types of soft gelatin capsule formulations of ALG-055009, Formulation 1 and Formulation 2, in approximately 8 healthy volunteers.
Study Start Date: March 25
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer Study
Intervention:
D...